Nearly 6 in 10 U.S. adults know that regularly consuming alcohol increases the chances of later developing cancer, a modest increase since early this year. The level of knowledge has rebounded to about where it was in early 2025, after the U.S. Surgeon General issued an advisory warning of the link between alcohol and cancer.

NCCN publishes its first-ever NCCN Guidelines for Patients focused specifically on how to support loved ones with cancer. The new NCCN Guidelines for Patients: Caregiving for People with Cancer provides an easy-to-understand guide for what to do in difficult situations and offers some much-needed lifelines.

The identity and abundance of gut microbes provide only part of the picture in colorectal cancer. A review from Fudan University and Tongji University brings together evidence on interactions among bacteria, archaea, fungi and viruses, genetic differences between microbial strains, and their effects on metabolism and host responses. Published in Microbiology China, it examines how these perspectives could inform biomarkers and targeted interventions, while emphasizing the need for stronger causal evidence and clinical validation.

The intestine engages in communication with various distant organs through neural, immune, and endocrine pathways. This systemic interconnection mechanism is referred to as the gut-organ axis, in which gut microbiota play a central role. The therapeutic landscape is rapidly evolving, with next-generation probiotics, postbiotics, and engineered strains now enabling precise, targeted remodeling of the gut ecosystem to restore host homeostasis and treat multi-organ diseases. This review articulates how the gut microbiota integrates environmental cues into a multi-organ regulatory network, underscoring its potential as a therapeutic target for systemic diseases.

The Asian Fund for Cancer Research Limited (AFCR) is pleased to announce the appointment of Mr. Sunil Tuli, Group CEO of King Power Group Hong Kong, to its Board of Directors.

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a phase 1 trial published in The Journal of Nuclear Medicine’s Late-Breaking Fast Track. Among patients treated with ²¹²Pb-ADVC001, 80 percent experienced a decline in prostate-specific antigen (PSA) levels of at least 50 percent, and the overall response rate was 100 percent. The findings support further clinical development of ²¹²Pb-ADVC001 to address the significant unmet needs in metastatic prostate cancer.